Quick Answer
Regenerative Medical Technology Group Inc. reported Gross Profit of $2.82 million for fiscal year 2024.
Regenerative Medical Technology Group Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $2.82M | +68.5% |
| 2023 | $1.68M | +91.1% |
| 2022 | $877.0K | +484.1% |
| 2021 | $150.1K | +1249.2% |
| 2020 | $11.1K | +143.8% |
| 2019 | -$25.4K | -39.5% |
| 2018 | -$18.2K | -174.6% |
| 2017 | $24.4K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $501.6K | -32.9% | -14.4% |
| June 30, 2025 | $585.8K | +11.2% | -37.9% |
| March 31, 2025 | $943.9K | +65.9% | +26.3% |
| September 30, 2024 | $747.1K | +65.9% | +41.8% |
| June 30, 2024 | $526.9K | +107.6% | -7.4% |
| March 31, 2024 | $569.0K | +6.0% | +26.4% |
| September 30, 2023 | $450.3K | +70.0% | +77.4% |
| June 30, 2023 | $253.8K | +72.7% | -52.7% |
- Regenerative Medical Technology Group Inc. showed an increase of +68.5% in Gross Profit compared to the prior fiscal year.
- Over the 2017–2024 period, Regenerative Medical Technology Group Inc.’s gross profit has grown by 11455.5% (from $24.4 thousand to $2.82 million).
- The most recent figure is from Regenerative Medical Technology Group Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: